Napo Pharmaceuticals
Crofelemer
A proprietary gastro-intestinal compound in clinical development for four distinct product indications
people
Scientific Advisor
Barry Quart, Pharm. D.
Dr. Quart is the President and CEO of Ardea Biosciences. He previously served as President and Chief Scientific Officer of Napo. Before joining Napo, he held the position of Senior Vice President, Pfizer Global Research and Development and the Director of the La Jolla Laboratories. Prior to that, he was President of Agouron Research and Development. Dr. Quart joined Agouron Pharmaceuticals in 1993 as Vice President, Regulatory Affairs. He has a Pharm. D. from University of California, San Francisco, and had spent over ten years at Bristol-Myers Squibb in both Clinical Research and Regulatory Affairs prior to joining Agouron. While at Bristol-Myers Squibb he was actively involved in the development and registration of nine important drugs, including paclitaxel, didanosine, stavudine, and sotalol. At Agouron, Dr. Quart was instrumental in the development and registration of Viracept®, which went from the lab bench to NDA approval in 38 months. Subsequent to the approval of Viracept® in 1997, Dr. Quart was promoted to Senior Vice President, Head of Drug Development at Agouron. In January 1999, Agouron became a division of the Warner-Lambert Company. In late 1999, Dr. Quart was promoted to President, Agouron Research and Development. In June 2000, Warner-Lambert was acquired by Pfizer, to create the world's largest pharmaceutical company. Within the newly created Pfizer Global Research and Development Division, Dr. Quart was appointed to the position of Senior Vice President, Director of the La Jolla Laboratories; this position was responsible for approximately 1000 employees and an annual budget of almost US$300 million. The majority of these employees were scientists working on discovery and development of drugs for the treatment of cancer and serious viral diseases, such as HIV. After the transition of Agouron R&D into the new Pfizer was completed, Dr. Quart decided to leave Pfizer to pursue other interests and joined Napo Pharmaceutials a year later.
